IHI call 12 puts applicants in the driving seat as the call invites them to identify ideas for novel public-private projects in the IHI Strategic Research and Innovation Agenda (SRIA). The deadline for proposals is 21 April 2026.
IHI call 12 has five topics, aligned with IHI’s five specific objectives as set out in the SRIA.
‘We want the health research community to explore our SRIA and bring forward novel, ambitious, public-private research projects with potential to transform European health and care,’ said IHI Executive Director Niklas Blomberg. ‘As a public-private partnership we are looking for projects that at the same time contribute to strengthening the competitiveness of the EU’s health industries and the implementation of relevant EU policies like the Life Sciences Strategy.’
Under IHI call 12, proposals will have to adhere to the philosophy of IHI. In other words, they will have to: address an unmet public health need; require a large-scale, ambitious, cross-sector, public-private partnership; have clearly-described impacts on society, the economy and science; and take account of the pre-competitive nature of IHI projects.
From an administrative point of view, HI call 12 will be a standard, single-stage call for proposals, meaning that applicants will have to ensure that half of their project’s costs are covered by in-kind contributions from IHI’s industry members and (if relevant) IHI contributing partners.
IHI call 12 builds on the success of IHI call 9, which was launched a year ago and piloted the applicant-driven approach. The projects resulting from IHI call 9 are just getting started now, and address topics as diverse as dementia, heart disease, and antimicrobial resistance as well as brain surgery, clinical trial design, and the use of artificial intelligence in healthcare.
Notes to editors
The full call text and details of how to apply can be found on the IHI call 12 page of the IHI website.
Press contact
Catherine Brett – External Relations Manager
Tel: +32 2 541 8214 | E-mail: catherine.brett@ihi.europa.eu
About IHI
The Innovative Health Initiative (IHI) aims to translate health research and innovation into real benefits for patients and society, and ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research. Health research and care increasingly involve diverse sectors. By supporting projects that bring these sectors together, IHI will pave the way for a more integrated approach to health care, covering prevention, diagnosis, treatment, and disease management.
IHI is a partnership between the European Union and European industry associations representing the pharmaceutical, medical technology, biotechnology, digital health and vaccine industries, namely COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe. IHI’s total budget is EUR 2.4 billion. Half of this comes from Horizon Europe, the EU’s research and innovation programme. The IHI industry partners have committed EUR 1 billion to IHI, and a further EUR 200 million can be committed by other organisations that decide to become Contributing Partners.
IHI builds on the successes of the Innovative Medicines Initiative (IMI), and the IHI Programme Office continues to manage the IMI project portfolio.
Website: ihi.europa.eu
LinkedIn profile | Bluesky: ihieurope | Mastodon: @IHIEurope@mastodon.social
